First-Ever gene therapy trial aims to restore vision in children with albinism
NCT ID NCT07313618
Summary
This early-stage study is testing a new gene therapy called JWK010 for children aged 5-12 with a specific type of albinism (OCA1). The goal is to see if a single injection into the eye is safe and can help the body produce pigment, which may improve vision and eye structure. Researchers will carefully monitor for side effects while measuring changes in vision, eye color, and eye movement.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULOCUTANEOUS ALBINISM (OCA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.